130 related articles for article (PubMed ID: 35995140)
1. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.
Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H
Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140
[TBL] [Abstract][Full Text] [Related]
2. The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications.
Langbein LE; El Hajjar R; Kim WY; Yang H
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1417-C1429. PubMed ID: 36154696
[TBL] [Abstract][Full Text] [Related]
3. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma.
Green YS; Ferreira Dos Santos MC; Fuja DG; Reichert EC; Campos AR; Cowman SJ; Acuña Pilarte K; Kohan J; Tripp SR; Leibold EA; Sirohi D; Agarwal N; Liu X; Koh MY
Oncogene; 2022 Oct; 41(42):4709-4723. PubMed ID: 36097192
[TBL] [Abstract][Full Text] [Related]
4. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
5. Evolution of the HIF targeted therapy in clear cell renal cell carcinoma.
Golijanin B; Malshy K; Khaleel S; Lagos G; Amin A; Cheng L; Golijanin D; Mega A
Cancer Treat Rev; 2023 Dec; 121():102645. PubMed ID: 37879247
[TBL] [Abstract][Full Text] [Related]
6. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
7. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis.
Dong B; Gao Y; Kang X; Gao H; Zhang J; Guo H; You MJ; Xue W; Cheng J; Huang Y
Oncotarget; 2016 Dec; 7(49):80435-80449. PubMed ID: 27741516
[TBL] [Abstract][Full Text] [Related]
8. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
[TBL] [Abstract][Full Text] [Related]
9. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.
Gregg JL; Turner RM; Chang G; Joshi D; Zhan Y; Chen L; Maranchie JK
Cancer Res; 2014 Jul; 74(13):3501-3511. PubMed ID: 24755467
[TBL] [Abstract][Full Text] [Related]
10. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner.
Todd VM; Vecchi LA; Clements ME; Snow KP; Ontko CD; Himmel L; Pinelli C; Rafat M; Johnson RW
Commun Biol; 2021 Sep; 4(1):1122. PubMed ID: 34556788
[TBL] [Abstract][Full Text] [Related]
12. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism.
Du W; Zhang L; Brett-Morris A; Aguila B; Kerner J; Hoppel CL; Puchowicz M; Serra D; Herrero L; Rini BI; Campbell S; Welford SM
Nat Commun; 2017 Nov; 8(1):1769. PubMed ID: 29176561
[TBL] [Abstract][Full Text] [Related]
13. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol accumulation in ccRCC: the role of ccRCC-initiating VHL-HIFα pathway.
Mohtar MA; Hasanah Mohd Yusuf SN; Syafruddin SE
EBioMedicine; 2024 May; 103():105112. PubMed ID: 38599011
[No Abstract] [Full Text] [Related]
15. Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein.
Rao H; Li X; Liu M; Liu J; Li X; Xu J; Li L; Gao WQ
Oncogene; 2020 May; 39(19):3853-3866. PubMed ID: 32161311
[TBL] [Abstract][Full Text] [Related]
16. TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy.
Huang Y; Xiong Z; Wang J; Gao Y; Cao Q; Wang D; Shi J; Chen Z; Yang X
J Transl Med; 2024 Feb; 22(1):212. PubMed ID: 38419050
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer.
Meléndez-Rodríguez F; Roche O; Sanchez-Prieto R; Aragones J
Front Oncol; 2018; 8():214. PubMed ID: 29938199
[TBL] [Abstract][Full Text] [Related]
18. State of the science: an update on renal cell carcinoma.
Jonasch E; Futreal PA; Davis IJ; Bailey ST; Kim WY; Brugarolas J; Giaccia AJ; Kurban G; Pause A; Frydman J; Zurita AJ; Rini BI; Sharma P; Atkins MB; Walker CL; Rathmell WK
Mol Cancer Res; 2012 Jul; 10(7):859-80. PubMed ID: 22638109
[TBL] [Abstract][Full Text] [Related]
19. Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer.
Schmid V; Lafleur VN; Lombardi O; Li R; Salama R; Colli L; Choudhry H; Chanock S; Ratcliffe PJ; Mole DR
Sci Rep; 2019 Dec; 9(1):18768. PubMed ID: 31822727
[TBL] [Abstract][Full Text] [Related]
20. Roles of the BAP1 Tumor Suppressor in Cell Metabolism.
Han A; Purwin TJ; Aplin AE
Cancer Res; 2021 Jun; 81(11):2807-2814. PubMed ID: 33446574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
